Abstract
Interferon beta is a new and expensive drug for treating multiple sclerosis. One published trial has shown that it reduces the exacerbation rate in patients who have relapsing-remitting disease without important disability. This paper describes the development of a strategy for purchasing the drug in one region of England before its licensing. Purchasers felt unable to decline funding for this marginally effective drug and thereby undertake explicit rationing. To ensure prescribing was within the guidelines, a vast communication network had to be sustained with managers, general practitioners, neurologists, the Multiple Sclerosis Society, and professional advisers in all the purchasing authorities. The workload involved was considerable. The dilemma of rationing in a public service with a high political profile is demonstrated.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Elborn J. S., Shale D. J., Britton J. R. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax. 1991 Dec;46(12):881–885. doi: 10.1136/thx.46.12.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
- Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):655–661. doi: 10.1212/wnl.43.4.655. [DOI] [PubMed] [Google Scholar]
- McDonald W. I. New treatments for multiple sclerosis. BMJ. 1995 Feb 11;310(6976):345–346. doi: 10.1136/bmj.310.6976.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meltzer H. Y., Cola P., Way L., Thompson P. A., Bastani B., Davies M. A., Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993 Nov;150(11):1630–1638. doi: 10.1176/ajp.150.11.1630. [DOI] [PubMed] [Google Scholar]
- Walley T., Barton S. A purchaser perspective of managing new drugs: interferon beta as a case study. BMJ. 1995 Sep 23;311(7008):796–799. doi: 10.1136/bmj.311.7008.796. [DOI] [PMC free article] [PubMed] [Google Scholar]